3D printed bioceramic for phage therapy against bone nosocomial infections

Phage therapy of pulmonary infections

It is generally agreed that a bacteriophage-associated phenomenon was first unambiguously observed one-hundred years ago with the findings of Twort in 1915. This was independently followed by complementary observations by d'Hérelle in 1917. D'Hérelle's appreciation of the bacteriophage phenomenon appears to have directly led to the development of phages as antibacterial agents within a variety ...

Promising natural products against nosocomial infections

Abstract Globally, increasing drug resistance among nosocomial infections is a growing concern for medicine, which demands effective therapeutic regimes. Along with existing major scaffolds, namely penicillin, cephalosporin, quinolones, macrolides and tetracyclines, exploring new antibiotics with novel scaffold is a pressing necessity to combat multi-drug resistant pathogens causing hospital as...

Nosocomial Infections: The Definition Criteria

Common Preconditions for Safe Phage Therapy of Pseudomonas aeruginosa Infections

One of the approaches to the treatment of infections caused by multiply-(MDR) or extra drugresistant (XDR) pathogenic strains may be application of bacterial viruses (bacteriophages)— phage therapy. Results of a long, but quite limited use of phage therapy in several Eastern European countries, as well as experiments on animal models in Western countries support the possibility to use phage the...

Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa

With an increase in cases of multidrug-resistant Pseudomonas aeruginosa, alternative and adjunct treatments are needed, leading to renewed interest in bacteriophage therapy. There have been few clinically relevant studies of phage therapy against chronic lung infections. Using a novel murine model that uses a natural respiratory inhalation route of infection, we show that phage therapy is an ef...